Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
SEATTLE - Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company with a market capitalization of $2.07 million, has released promising data from its ongoing clinical trials for mipletamig, a novel treatment for acute myeloid leukemia (AML). The company announced that in combination with standard of care, mipletamig has achieved remission in 90% of frontline AML patients across two trials. According to InvestingPro analysis, while the company maintains a favorable cash-to-debt position, its overall financial health score stands at 1.31, indicating potential challenges ahead.
The RAINIER trial, which is currently enrolling patients, has not observed any cases of cytokine release syndrome, indicating a favorable safety profile for the drug. This safety aspect is critical as cytokine release syndrome is a common side effect with similar treatments. Aptevo attributes this to the engineered CD3 binding domain and its proprietary ADAPTIR® platform technology.
In addition to the RAINIER trial, data from earlier studies have shown that 100% of patients achieved remission within the first 30 days. Furthermore, one patient reached complete remission with minimal residual disease-negative status, a significant indicator of potential long-term remission and improved survival rates.
The company has also reported a decrease in research and development expenses and general and administrative expenses, with a net loss of $6.3 million for the quarter ended March 31, 2025. Aptevo’s cash position as of the end of March 2025 was $2.1 million, not including approximately $4.9 million raised in April and May 2025. InvestingPro data reveals the company’s EBITDA stands at -$24.25 million for the last twelve months, with a current ratio of 1.72, suggesting adequate short-term liquidity despite operational losses.
Mipletamig is part of Aptevo’s focus on developing bispecific immunotherapies for cancer treatment. The company’s pipeline includes another clinical candidate, ALG.APV-527, and three pre-clinical candidates. Aptevo anticipates multiple data readouts in 2025 and plans to present results at the American Society of Hematology meeting in the fourth quarter. With the stock trading near its 52-week low of $0.33, InvestingPro subscribers have access to 12 additional key insights about Aptevo’s financial health and market position, helping investors make more informed decisions.
The information in this report is based on a press release statement from Aptevo Therapeutics.
In other recent news, Aptevo Therapeutics has announced several developments related to its stock offerings and clinical programs. The company filed a prospectus supplement with the SEC to offer common stock, aiming to raise up to $3,167,548 under an At The Market Offering Agreement with Roth Capital Partners. Additionally, Aptevo has entered into a separate agreement to sell shares worth approximately $2,959,952 through Roth, with a commission of 3% on gross sales. In a registered direct offering, Aptevo plans to sell 2,324,000 shares at $0.862 each, raising around $2 million to support clinical development and corporate purposes. Furthermore, a securities purchase agreement was initiated for a direct offering and warrants sale, expected to generate about $2.1 million in gross proceeds. On the clinical front, Aptevo reported progress on its preclinical compound APVO603, which targets solid tumors and shows potential in enhancing immune responses. Their lead candidate, Mipletamig, is in a Phase 1b/2 trial for acute myeloid leukemia, demonstrating promising early results. These developments reflect Aptevo’s ongoing efforts to fund its operations and advance its oncology pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.